DUBLIN--(BUSINESS WIRE)--The "DP1 Receptor (Prostaglandin D2 receptor) Antagonist -Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:
- Clinical
- Non-clinical
- Inactive: Discontinued and/or Dormant
Descriptive coverage of pipeline development activities for DP1 Receptor (Prostaglandin D2 receptor) Antagonist - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Key Topics Covered:
1. Report Introduction
2. DP1 Receptor (Prostaglandin D2 receptor) Antagonist - Overview
4. Comparative Analysis
5. DP1 Receptor (Prostaglandin D2 receptor) Antagonist Pipeline Products in Clinical Stages
6. DP1 Receptor (Prostaglandin D2 receptor) Antagonist Pipeline Products in Non-clinical Stages
8. Inactive Pipeline Products
- Merck Sharp & Dohme
- Ligand Pharmaceuticals
- Atopix Therapeutics
- AstraZeneca
- 7TM Pharma
- Shionogi
- Novartis
- Boehringer Ingelheim
- Actelion Pharmaceuticals
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/5w6w73/dp1_receptor?w=4
